Elizabeth Nielson and Ingmar Gorman - The Importance of Psychedelic Integration Training for Therapists
Release Date: 02/18/2020
Psychedelics Today
Overview Evelyn Eddy Shoop PMHNP-BC joins Psychedelics Today to share her journey from Division I athlete to psychiatric mental health nurse practitioner and psilocybin research participant. In this conversation, she explains how sports injuries, OCD, and intensive treatment led her into psychiatry and eventually into a psilocybin clinical trial at Yale. Her story weaves together lived experience, clinical training, and a call for more humane systems of care and better qualitative data in psychedelic science. Early Themes: Injury, OCD, and Choosing Psychiatry Early in the episode, Evelyn...
info_outlinePsychedelics Today
In this episode, Joe Moore sits down with Dr. Jason Konner, a longtime oncologist who recently left his full-time clinical role at to devote himself to the emerging intersection of cancer care and psychedelics. Dr Konner shares how, after more than two decades treating people, he hit a wall. The accumulated grief, constant exposure to death, and intensity of oncology left him deeply , though he didn’t have that language for it at the time. A chance moment in a yoga class, overhearing someone say “ retreat” just before he was scheduled for hernia surgery, became the turning point....
info_outlinePsychedelics Today
Clinical psychologist Dr. Genesee Herzberg joins Kyle to reflect on two decades in trauma work and 15 years inside the psychedelic ecosystem—from early MAPS conferences to running Sage Integrative Health. She traces how personal psychedelic experiences set her on a path of service, research at CIIS on MDMA-assisted therapy, and hands-on roles with MAPS: Zendo Project harm reduction, adherence rating, and ultimately serving as an MDMA therapist in clinical trials. Today she leads Sage, an integrative clinic (psychotherapy, psychiatry, bodywork, acupuncture, and functional nutrition) focused...
info_outlinePsychedelics Today
Clinical psychologist joins to share insights from her decade of work with and her evolving focus on community-based integration. As the former Clinical Lead for , Dr. Watts witnessed how psychedelic experiences can foster profound feelings of — to self, others, and nature — yet also how that connection can fade without ongoing support. In this conversation, she reflects on what years of research have taught her about connectedness as both a healing mechanism and a human need. She explores how can transform fleeting psychedelic breakthroughs into lasting change, and why community is...
info_outlinePsychedelics Today
Artist, builder, and podcast host Jennifer Espenscheid joins Joe Moore for a rich conversation on creativity, process, and the spiritual dimensions of making art. Drawing from her South Dakota roots and large-scale works like Luciferia, Jennifer reflects on the blend of grit, intuition, and trust that guides her artistic life. She discusses how psychedelics have served as a tool for clarity and healing rather than direct creation of art, helping her dissolve patterns and reconnect to innate creativity. They explore how events like Burning Man catalyze inspiration, why intention and...
info_outlinePsychedelics Today
Brad Adams — LAMPS (Los Angeles Psychedelic Society) joins Kyle to trace his path from PhD researcher to community builder. Brad shares how early work in AIDS, Alzheimer’s, gerontology, and cancer research primed him to notice Harbor-UCLA’s psilocybin pilot for stage-4 cancer patients with death anxiety—where the strongest mystical experiences correlated with profound death acceptance. Teaming with Dennis McKenna, he ran an ayahuasca pilot in Peru and presented findings at Psychedelic Science 2017. From there, Brad founded LAMPS: first as research meetups at UCLA, then as a thriving...
info_outlinePsychedelics Today
In this episode, Kyle and Joe sit down with filmmaker Mustapha Khan and Dreamshadow’s Elizabeth & Lenny Gibson to explore Life and Breath—a new documentary immersing viewers in the experience and community of Holotropic Breathwork. We talk about why Mustapha was drawn to Dreamshadow, the film’s cinéma vérité approach that places you “in the room,” and how years of facilitation informed what became both an archival record and a living portrait of transformation. Elizabeth and Lenny reflect on 35+ years of holding space, the role of curiosity over agenda, and why genuine...
info_outlinePsychedelics Today
In this episode, Joe Moore talks with Megan Portnoy, a doctoral candidate in clinical psychology at Antioch University New England, about how can reshape the environments used in psychedelic-assisted therapy. Megan explains how physical space is not just a backdrop but an active participant in the therapeutic process, influencing emotion, cognition, and healing. She recently for her presentation on this topic at . They explore how design principles that foster awe, play, and flexibility can deepen integration and expand what’s possible in clinical settings. The conversation also...
info_outlinePsychedelics Today
Joe and Kyle open with reflections from their first r/psychonaut AMA, then pivot to why they’re building Navigators—our off-social community with book/film clubs, early ad-free episodes, mentorship, and an expanding education library. The core discussion explores touch and bodywork in breathwork and psychedelic contexts: why defaulting to “no touch” and moving slowly matters; informed consent; reading nonverbals; and keeping client agency central. They unpack trauma-informed concepts like the window of tolerance, polyvagal‐adjacent ideas (and critiques), and the ethics of avoiding...
info_outlinePsychedelics Today
Interviewers: Joe Moore & Anne Philippi Guests: TK Wonder & Cipriana Quann (The Quann Sisters) Recorded: June 18 during MAPS PS 2025 Content note: This episode discusses childhood sexual, physical, and emotional abuse, suicidal ideation, disordered eating, and recovery. Identical twins, writers, and culture-shapers TK Wonder and Cipriana Quann join Joe and Anne for a frank, generous conversation about identity, resilience, and the long arc of healing. Cipriana recounts launching Urban Bush Babes in 2011 to center women of color in beauty and fashion—work that led to a Vogue...
info_outlineIn this Episode, Kyle sits down with Elizabeth Nielson and Ingmar Gorman, Co-founders of Fluence, Training in Psychedelic Integration. They are both therapists on the MAPS clinical trial for MDMA Assisted Psychotherapy for PTSD.
3 Key Points:
- Elizabeth and Ingmar are co-founders of Fluence, an online Psychedelic Integration Training program.
- If psychedelic treatments become available more widely, the fear is that therapists won't be as educated on how to handle their patient interactions based on the behavior of each psychedelic. Psychedelic Integration Therapy Training is so important.
- There are 3 phases to the MDMA for PTSD clinical trial. Phase 1 would be pre-clinical data about the chemistry of a drug, Phase 2 is where you begin to test your treatment in a patient population, and Phase 3 is where you get the data to demonstrate that the treatment is superior to a placebo and other treatments in general.
Support the show
- Patreon
- Leave us a review on iTunes
- Share us with your friends – favorite podcast, etc
- Join our Facebook group - Psychedelics Today group – Find the others and create community.
Navigating Psychedelics
Show Notes
About Ingmar
- Ingmar is a previous guest of the show
- He is a private Investigator for the MAPS MDMA trial
- He is a therapist and the Co-founder of Fluence
About Elizabeth
- Elizabeth is a Clinical Psychologist
- She has a long history in working with clinical trials as a therapist
- She is part of the psychedelic education and continuing care program
- She does a lot of supervision and training for therapists
The Trial
- The approval of expanded access by the FDA includes 50 people in total
- They are near the end of MAP 1 (out of MAP 1 and MAP 2)
- When they transition into MAP 2, it will be a little more refined
- MAP 2 is different participants than MAP 1
- There are 3 phases
- Phase 1 would be pre-clinical data about chemistry of a drug and how it metabolises, if its poisonous, etc
- Phase 2 is where you begin to test your treatment in a patient population
- Phase 3 is where you get the data to demonstrate that the treatment is superior to a placebo and other treatments in general
- They are done as a double-blind trial, both the therapist and patient don't know if the patient is receiving the treatment or now
Take-aways
- There is a lot of information that has to be shared effectively
- The therapists are very much in the lives of the participants on top of just the MDMA
- Instead of learning from the trials of what to do on a practical level, its about inspiring them to bring this as an actual treatment for people
- The multiple ways that PTSD can manifest and look like, and the may ways that MDMA can look like when administered, have some commonalities
- The deepening, the broadening, the way they communicate, can all be the same
- Ingmar holds the belief in the inner healing intelligence of all people
- One of the first things he does when he begins with a new patient, he says that this is something he really believes in, and his role as a therapist to help them in their own healing process and mechanism
- What Elizabeth wanted to learn, know and practice while she was going through school, isn't what she she thought it was until she found it
- She says this work really requires them to trust people's minds and experiences
- There is something that they tell their patients, “Don't get ahead of the medicine” - Elizabeth
- There is an interesting paradox between not knowing and following intuition, to having an actual method and following that
- There is a sweet spot between following a script to following your intuition as a therapist
- You want to trust that inner healer process of the patient, but also need to know when to intervene (usually from a safety standpoint)
Fluence
- 3 days after Horizons, Elizabeth was at home with a cold, and talked to Ingmar that morning curious for a name for the project
- Fluence means, magical or mystical power or source of power
- It can also refer to the density of particles of energy
- They teach about harm reduction and integration with their patients in their practice
- They aren't teaching protocols in the workshops, they just think the harm reduction is important
- The last part of integration is mindfulness
- Ingmar’s biggest influence are his clients and patients, he is so inspired by them
- A large piece of the motivation for creating Fluence is from patients just looking for someone to talk about their experience with
The Why
- A mother whose teenage daughter with depression, reached out to Ingmar with trouble trying to treat her depression
- The family decided it would be a good idea to use Ketamine therapy, which was successful
- She was doing so well, so well that she then went to a therapist to integrate it
- The therapist that she went to then instead of responding positively, decided to fire the teen for further therapy, and report the parents to child care services for providing ketamine therapy
- Ingmar says their position is not that everyone needs psychedelic integration therapy, its specifically for those that don't feel supported by family or community, and it gives them a professional service as an option
- "Psychedelics are not 10 years of change in one night, they are 10 years of insight in one night. integration is so important." - Elizabeth
- The goal is to support people in making a change that feels safe and right for them
- If the treatments become available more widely, the fear is that therapists won't be as educated on how to handle their patient interactions based on the behavior of each psychedelic
- Mental health practitioners can be a great source for working through those experiences
Menla Training
- Menla Training
- They could really take their time with the process and training
- The trainings that they had gone to has made their own Fluence courses better
- In 2019 they had 5 of the trainings for clinicians, and the trainings will be better and better as they go
Ketamine Infusion Therapy
- The experience is not dose dependent
- The purpose of the workshop is to educate both therapists and doctors about what can happen in psychotherapy
Links
Psychedelics 101 and 102 Workshop at ICPR 2020
About Elizabeth

Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment PTSD, and psilocybin-assisted treatment of treatment resistant depression. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her program of research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.
About Ingmar

Dr. Ingmar Gorman is a co-founder of Fluence and a psychologist who specializes in assisting populations who have a relationship with psychedelics. He is the site co-principal investigator and therapist on a Phase 3 clinical trial studying MDMA-assisted psychotherapy for post-traumatic stress disorder. Dr. Gorman is a board member of Horizons Media, Inc., a not for-profit educational charity and organizer of the Horizons Conference: Perspectives on Psychedelics. After completing his NIH postdoctoral fellowship at New York University, Dr. Gorman stepped down as director of the Psychedelic Education and Continuing Care Program to focus his efforts on Fluence and the training of future therapists.
Get a 30 day free audible trial at audibletrial.com/psychedelicstoday


